BLASINGLE-DOSEVIAL
Approved
Jun 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
5/8 — Partial
KANJINTI (trastuzumab-anns) by Amgen is her2/neu/cerbb2 antagonists [moa]. Approved for her2/neu receptor antagonist [epc]. First approved in 2019.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KANJINTI (trastuzumab-anns) is a biosimilar monoclonal antibody that targets HER2/neu receptors, used to treat HER2-positive breast cancer and gastric cancers. It works by blocking HER2 signaling, which is overexpressed in these malignancies. As an Amgen biosimilar approved in 2019, it provides an alternative to originator trastuzumab (Herceptin) with comparable clinical efficacy.
$0.004BPart D
PeakKANJINTI is in peak commercial phase with $4M Part D spending (875 claims, 2023), indicating established market penetration but modest volume compared to competitors; small commercial team likely focused on market maintenance and payer relationships.
Mechanism of Action
HER2/Neu/cerbB2 Antagonists
Pharmacologic Class:
HER2/neu Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KANJINTI offers limited new career growth opportunities; zero linked job openings reflect a mature biosimilar in competitive equilibrium with modest Part D spending ($4M). Working on this product means contributing to market defense and payer negotiations rather than launching or scaling a high-growth asset.
Brand Manager
Worked on KANJINTI at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.